A Phase I trial of RTX (resiniferatoxin) for moderate to severe osteoarthritis pain

Trial Profile

A Phase I trial of RTX (resiniferatoxin) for moderate to severe osteoarthritis pain

Planning
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Resiniferatoxin (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Apr 2018 New trial record
    • 28 Mar 2018 According to a Sorrento Therapeutics media release, the Company expects to file IND and enroll first patient in this trial in 1H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top